Tokyo — Terumo Corporation (TSE: 4543 Section 1) and Biosensors International Group, Ltd. ("Biosensors", Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20) announced today an extension of their existing licensing agreements, under which Terumo can continue to incorporate BioMatrix™ technology in the production, marketing and selling of Terumo's Nobori® drug-eluting stent (DES) systems in markets worldwide, outside of the United States.Terumo and Biosensors have agreed to extend the original licensing agreement for territories outside of Japan until December 2014. During the original term of such agreement for Japan, Terumo continues to benefit from its existing rights in Japan to manufacture, market and sell its Nobori® DES systems incorporating BioMatrix™ technology.Under the original agreements, Terumo began introducing its Nobori® DES system in global markets outside of Japan and the United States in 2008, and in Japan in 2011. Nobori® is now sold in over 20 countries across Europe, Asia and Latin America. Nobori® incorporates both Biolimus A9™ (BA9™), an anti-restenotic drug developed and patented by Biosensors specifically for use with stents, as well as Biosensors' unique abluminal biodegradable polymer coating.
This is HCP only content
website and cannot be refused. Other cookies are only placed if you choose to do so. For further information, please read our cookies policy.
Essential cookies to ensure the website functions well.
Cookies to help us measure the general use of our website.
Cookies that save personal information while browsing.